Genakumab for injection

DRUG3 trials

Sponsors

Changchun GeneScience Pharmaceutical Co., Ltd.

Conditions

Acute GoutGoutGout FlareGout Initiating Urate-loweringUrate-lowering Therapy

Phase 1

Clinical Study of Genakumab for Injection in Patients With Acute Gout

CompletedNCT05328531

Changchun GeneScience Pharmaceutical Co., Ltd.Acute Gout

Start: 2021-05-22End: 2022-06-09Updated: 2025-02-27

Phase 2

Safety and Efficacy of Genakumab for Injection in Patients With Gout Flare

CompletedNCT05936268

Changchun GeneScience Pharmaceutical Co., Ltd.Acute Gout, Gout Flare

Start: 2023-07-21End: 2024-02-28Updated: 2024-11-08

A Study of the Efficacy of Genakumab in Prevention of Acute Flares in Gout Patients Initiating Urate-lowering TherapyUrate-lowering (GenSci048-202)

CompletedNCT05936281

Changchun GeneScience Pharmaceutical Co., Ltd.Gout, Gout Initiating Urate-loweringUrate-lowering Therapy

Start: 2023-07-20End: 2024-01-19Updated: 2025-01-01

Related Papers

Efficacy and Safety of Firsekibart Compared to Etoricoxib for Gout Flares: A Phase 2, Multicenter, Open-label, Active-controlled, Randomized Non-inferiority Trial

Rheumatology and Therapy2025-08-202 citations